HOME
>
臨床医学：内科
>
消化器一般
> DATA　UPDATA消化管

DATA　UPDATA消化管

出版社：	先端医学社
著者：	浅香正博　寺野　彰　日比紀文／編
発行日：	2001-06-01
分野：	臨床医学：内科 > 消化器一般
電子書籍版：	2001-06-01 （第1版第1刷）

書籍・雑誌

≪全国送料無料でお届け≫

取寄せ目安：8～14営業日

5,170 円(税込)

購入する

電子書籍

章別単位で購入

ブラウザ、アプリ閲覧

2,585 円(税込)

購入する

商品紹介

序文より：最近とにくこの１０年間、消化管疾患の治療方法は根本的な変革を遂げた。ことに消化性潰瘍や慢性胃炎、あるいは低悪性度MALTリンパ腫などの治療は、Helicobacter pyloriの登場によって、疾患概念自体の変化により、感染症の治療として位置付けられるようになってきた。これまでも、H2体拮抗薬さらにプトンポンプ阻害薬の出現で大きな変化を受けていた消化性潰瘍の治療法は、さらにコペルニクス的展開を遂げたといえる。

目次

DATA UPDATA消化管

目次
上部消化管ＰａｒｔＩ　食道疾患
　バルーン拡張術・手術危険群の食道アカラシア患者に対してニフェジピン投与は推奨される
　ボツリヌス毒素の食道下部括約筋への局注は食道アカラシアに対して有用である
　ボツリヌス毒素局注療法は食道アカラシアに対してバルーン拡張術と同程度に有用である
　逆流性食道炎の再発予防には、オメプラゾールの連日投与が間欠投与よりもすぐれている
　他
上部消化管ＰａｒｔＩＩ　胃・十二指腸疾患
　急性胃粘膜病変に対するレバミピドの臨床評価
　内視鏡的に、びらん、出血、発赤についてセトラキサートの効果を評価し、全体の改善度は1

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

上部消化管PART I●食道疾患

P.13 掲載の参考文献

1) Berger K, NcCallum RW: Nifedipine in the treatment of achalasia. Ann lntern. Med 96: 61-62, 1982

2) Triadafilopoulos G, Aaronson M, Sackel S et al: Medical treatment of esophageal achalasia. Double-blind crossover study with oral nifedipine, verapamil, and placebo. Dig Dis Sci 36: 260-267, 1991

3) Bassotti G, Annese V: Review article: pharmacological options in achalasia・Aliment Pharmacol Ther 13: 1391-1396, 1999

P.15 掲載の参考文献

1) Pasricha PJ, Ravich WJ, Kalloo AN: Effects of intrasphincteric botulinum toxin on the lower esophageal sphincter in piglets. Gastroenterology 105: 1045-1049, 1993

2) Pasricha PJ, Ravich WJ, Hendrix TR et al: Treatment of achalasia with intrasphincteric injection of botulinum toxin. A pilot trial. Ann lntern Med 121: 590-591, 1994

3) Vaezi MF, Richter JE: Current therapies for achalasia: comparison and efficacy. J Clin Gastroenterol 27: 21-35, 1998

P.17 掲載の参考文献

1) Pasricha PJ, Rai R, Ravich WJ et al: Botulinum toxin for achalasia: long-term outcome and predictors of response. Gastroenterology 110: 1410-1415, 1996

2) Panaccione R, Gregor JC, Reynolds RP et al: Intrasphincteric botulinum toxin versus pneumatic dilatation for achalasia: a cost minimization analysis. Gastrointest Endosc 50: 492-498, 1999

3) Annese V, Bassotti G, Coccia G et al: A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. Gut 46: 597-600, 2000

P.19 掲載の参考文献

1) Dent J, Yeomans ND, Mackinnon M et al: Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 35: 590-598, 1994

2) Zeitoun P, Barbier P, Cayphas JP et al: Comparison of two dosage regimen of reflux esophagitis-10mg once daily and 20mg weekends-as prophylaxis against reccurence of reflux esophagitis. Hepatogastroenterology 36: 279-280, 1989

3) Crobach LF, Jansen JB, Lamers CB: Effect of intermittent weekend therapy with omeprazole on basal and bombesin-and pentagastrin-stimulated gastric acid and serum gastrin. Scand J Gastroenterol 23: 407-412, 1988

P.21 掲載の参考文献

1) Havelund T, Laursen LS, Skoubo-Kristensen E et al: Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial. Br Med J 296: 89-92, 1988

2) Hetzel DJ, Dent J, Reed WD et al: Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95: 903-912, 1988

3) Lundell L, Westin IH, Sandmark S et al: Omeprazole or high dose ranitidine in the treatment of patients with reflux oesophagitis not responding to standard doses of H2-receptor antagonists. Gastroenterology 96: A310, 1989

P.23 掲載の参考文献

1) Jones R, Crouch SL: Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. Aliment Pharmacol Ther 13: 413-419, 1999

2) Hatlebakk JG, Berstad A: Lansoprazole 15 and 30mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. Aliment Pharmacol Ther 11: 365-372, 1997

P.26 掲載の参考文献

1) Bate CM, Keeling PW, O'Morain C et al: Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations. Gut 31: 968-972, 1990

2) Klinkenberg-Knol EC, Jansen JMB, Festen HPM et al: Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux esophagitis. Lancet 1: 349-351, 1987

3) Sandmark S, Carlsson R, Fausa O et al: Omeprazole or ranitidine in the treatment of reflux esophagitis: results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol 23: 625-632, 1988

P.29 掲載の参考文献

1) Vigneri S, Termini R, Leandro G et al: A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 333: 1106-1110, 1995

2) Bell NJV, Hunt RH: Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 33: 118-124, 1992

P.31 掲載の参考文献

1) Hetzel DJ, Dent J, Reed WD et al: Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95: 903-912, 1988

P.33 掲載の参考文献

1) Robinson M, Sahba B, Avner D et al: A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group. Aliment Pharmacol Ther 9: 25-31, 1995

P.35 掲載の参考文献

1) Orr WC, Finn A, Wilson T et al: Esophageal acid contact time and heartburn in acute treatment with ranitidine and metoclopramide. Am J Gastroenterol 85: 697-700, 1990

2) Chiba N, De Gara CJ, Wilkinson JM et al: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 112: 1798-1810, 1997

P.37 掲載の参考文献

1) Orr WC, Robinson MG, Humphries TJ et al: Dose-response effect of famotidine on patterns of gastroesophageal reflux. Aliment pharmacol Ther 2: 229-235, 1988

2) Robinsen M, Decktor DL, Stone RC et al: Famotidine (20mg) b. d. relieves gastrooesophageal reflux symptoms in patients without erosive oesophagitis. Aliment pharmacol Ther 5: 631-643, 1991

3) Wesdorp IC: Famotidine in gastroesophageal reflux disease (GERD) . Hepatogastroenterology 39 (suppl 1): 24-26, 1992

P.39 掲載の参考文献

1) Rowinsky EK, Citardi MJ, Noe DA et al: Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol 119: 727-733, 1993

2) Bhalla KN, Kumar GN, Walle T et al: Phase I and pharmacokinetic trial of a 3-hour infusion of Taxol, Cisplatin plus 5-fluorouracil in advanced solid tumors. Proc Am Soc Clin Oncol 13: 165, 1994

P.41 掲載の参考文献

1) Lokich J, Anderson N, Moore C et al: Paclitaxel, cisplatin and etoposide combination chemotherapy: a comparison of dose intensity in two multifractionated dose schemas. Eur J Cancer 34: 664-667, 1998

2) 根来俊一: 進行非小細胞肺癌の治療. 癌と化学療法 25: 1671-1679, 1998

3) 上岡博: 肺癌に対する新しい併用療法. 癌と化学療法27: 356-361, 2000

P.43 掲載の参考文献

1) Lippman SM, Parkinson DR, Itri LM et al: 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer lnst 84: 235 241, 1992

2) LipPman SM, Kavanagh JJ, Paredes-Espinoza M et al: 13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer lnst 84: 241-245, 1992

上部消化管PART II●胃・十二指腸疾患

P.48 掲載の参考文献

1) 竹本忠良ほか: AGMLの臨床および研究の展望. 消化器内視鏡2: 759-765, 1990

2) 木村健ほか: 急性胃粘膜病変の診断. 臨床消化器内科3: 1397-1406, 1988

3) 竹本忠良ほか: 急性胃炎, 慢性胃炎の急性増悪期に対するrebamipideの用量設定試験-二重盲検比較試験による2用量の比較検討-. 臨床成人病 23: 1163-1190, 1993

4) 小林絢三ほか: 急性胃炎, 慢性胃炎の急性増悪期に対するrebamipideの臨床評価-二重盲検法による服用時期の比較検討-. 臨床成人病 23: 1003-1028, 1993

P.51 掲載の参考文献

1) Konturek SJ, Brzozowski T, Mach T et al: Importance of an acid milieu in the sucralfate-induced gastroprotection against ethanol damage. Scand J Gastroenterol 24: 807-812, 1989

2) Konturek JW, Hengst K, Konturek SJ et al: Physiological role of cholecystokinin in gastroprotection in humans. Am J Gastroenterol 93: 2385-2390, 1998

P.53 掲載の参考文献

1) Alderman BM, Cook GA, Familari M et al: Resistance to apoptosis is a mechanism of adaptation of rat stomach to aspirin. Am J Physiol Gastrointest Liver Physiol 278: 839-846, 2000

2) Donnelly MT, Goddard AF, Filipowicz B et al: Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury. Aliment Pharmacol Ther 14: 529-534, 2000

3) Lanza FL, Rack MF, Li Z et al: Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs aspirin In healthy postmenopausal women[In Process Citation]. Aliment Pharmacol Ther 14: 1663-1670, 2000

4) Levy DJ: Images in clinical medicine. An aspirin tablet and a gastric ulcer. N Engl J Med 343: 863, 2000

5) Mitobe Y, Hiraishi H, Sasai T et al: The effects of aspirin on antioxidant defences of cultured rat gastric mucosal cells. Aliment Pharmacol Ther 14 (suppl 1): 10-17, 2000

6) Mourad FH, Khuri M, Shouaib F et al: Protective effect of the nitric oxide donor molsidomine on indomethacin and aspirin-induced gastric injury in rats. Eur J Gastroenterol Hepatol 12: 81-84, 2000

7) Ranta-Knuuttila T, Mustonen H, Kivilaakso E: Topical prostaglandin E2 protects isolated gastric mucosa against acidified taurocholate-, but not ethanol-or aspirin-induced injury. Dig Dis Sci 45: 99-104, 2000

8) Sorensen HT, Mellemkjaer L, Blot WJ et al: Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 95: 2218-2224, 2000

9) Sugimoto N, Yoshida N, Yoshikawa T et al: Effect of vitamin E on aspirin-induced gastric mucosal injury in rats. Dig Dis Sci 45: 599-605, 2000

P.55 掲載の参考文献

1) Fuji Y, Matsura T, Kai M et al: Protection by polaprezinc, an anti-ulcer drug, against indomethacin-induced apoptosis in rat gastric mucosal cells[In Process Citation]. Jpn J Pharmacol 84: 63-70, 2000

2) Fujii Y, Matsura T, Kai M et al: Mitochondrial cytochrome c release and caspase-3-like protease activation during indomethacin-induced apoptosis in rat gastric mucosal cells. Proc Soc Exp Biol Med 224: 102-108, 2000

3) Lempinen M, Inkinen K, Wolff H et al: Matrix metalloproteinases 2 and 9 in indomethacin-induced rat gastric ulcer. Eur Surg Res 32: 169-176, 2000

4) Mourad FH, Khuri M, Shouaib F et al: Protective effect of the nitric oxide donor molsidomine on indomethacin and aspirin-induced gastric injury in rats. Eur J Gastroenterol Hepatol l2 : 81-84, 2000

5) Podvigina TT, Bogdanov AI, Filaretova LP: [The role of glucocorticoids in healing of indomethacin-induced lesions in the rat gastric mucosa]. Ross Fiziol Zh I M Sechenova 86: 720-727, 2000

6) Slomiany BL, Slomiany A: Role of endothelin-converting enzyme-1 in the suppression of constitutive nitric oxide synthase in rat gastric mucosal injury by indomethacin. [In Process Citation]. Scand J Gastroenterol 35: 1131-1136, 2000

P.57 掲載の参考文献

1) Hahn BA, Kirchdoerfer LJ, Fullerton S et al: Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome. Aliment Pharmacol Ther 11 : 547-552, 1997

2) Wiklund IK, Junghard O, Grace E et al: Quality of Life in Reflux and Dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD) . Eur J Surg Suppl (583): 41-49, 1998

3) Wong E, Guyatt GH, Cook DJ et al: Development of a questionnaire to measure quality of life in patients with irritable bowel syndrome. Eur J Surg Suppl (583): 50-56, 1998

4) Talley NJ, Verlinden M, Jones M: Validity of a new quality of life scale for functional dyspepsia: a United States multicenter trial of the Nepean Dyspepsia Index. Am J Gastroenterol 94: 2390-2397, 1999

5) Drossman DA, Patrick DL, Whitehead WE et al: Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire・Am J Gastroenterol 95: 999-1007, 2000

P.59 掲載の参考文献

1) Talley NJ, Axon A, Bytzer P et al: Management of uninvestigated and functional dyspepsia: a Working Party report for the World Congresses of Gastroenterology 1998. Aliment Pharmacol Ther 13: 1135-1148, 1999

P.61 掲載の参考文献

1) Veldhuyzen van Zanten SJO, Cleary C, Talley NJ et al: Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol 91: 660-673, 1996

P.63 掲載の参考文献

1) Verdu EF, Armstrong D, Idstrom JP et al: Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and Helicobacter pylori-associated gastritis. Scand J Gastroenterol 31: 1151-1156, 1996

2) Junghard O, Lauritsen K, Talley NJ et al: Validation of seven graded diary cards for severity of dyspeptic symptoms in patients with non ulcer dyspepsia. Eur J Surg Suppl 1: 106-111, 1998

3) Talley NJ: A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia. Gastroenterology 106: 1174-1183, 1994

P.65 掲載の参考文献

1) Talley NJ, Hunt RH: What role does Helicobacter pylori play in dyspepsia and nonulcer dyspepsia? Arguments for and against H. pylori being associated with dyspeptic symptoms. Gastroenterology 113 (suppl): S67-S77, 1997

2) Gilvarry J, Buckley MJ, Beattie S et al: Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia. Scand J Gastroenterol 32: 535-540, 1997

P.67 掲載の参考文献

1) Walt RP, Gomes M de FA, Word EC et al: Effect of daily oral omeprazole on 24 hour intragastric acidity. Br Med J 287: 12-14, 1983

2) Gustavsson S, Adami HO, L??f L et al: Rapid healing of duodenal ulcers with omeprazole: double-blind dose-comparative trial. Lancet 2: 124-125, 1983

3) Scandinavian Multicentre Study: Gastric acid secretion and duodenal ulcer healing during treatment with omeprazole. Scand J Gastroenterol 19: 882-884, 1984

P.70 掲載の参考文献

1) Classen M, Dammann HG, Domschke W et al: Abheilungsraten nach Omeprazol-und Ranitidin- Behandlung des Ulcus ventriculi: ergebnisse einer deutchen Multizenterstudie. Dtsch Med Wochenschr 110: 628-633, 1985

2) Lanzon-Miller S, Pounder RE, Hamilton MR et al: Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1 : 239-251, 1987

P.73 掲載の参考文献

1) Walan A, Bianchi-Porro G, Hentschel E et al: Maintenance treatment with cimetidine in peptic ulcer disease for up to 4 years. Scand J Gastroenterol 22: 397-405, 1987

2) Penston JG: Maintenance treatment versus no maintenance treatment in patients with duodenal ulcer disease. Scand J Gastroenterol 25 (suppl177): 42-51, 1990

3) Jensen DM, You S, Machicado GA et al: Long-term recurrence rates of peptic ulceration and rebleeding with H2 maintenance, surgery or no maintenance therapy. Gastroenterology 96: A239 (abstract), 1989

P.75 掲載の参考文献

1) Fries JF: NSAID gastropathy: Epidemiology. J Musculoskeletal Med 8: 21-28, 1991

2) Kobayashi K, Mizushima Y, Yanagawa A et al: Prophylactic effects ranitidine, a H2 receptor antagonist, on gastric and duodenal lesions induced by nonsteroidal anti-inflammatory agents. J Adult Dis 20: 253-264, 1990

3) Naito Y, Yoshikawa T, Tanigawa T et al: Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radic Biol Med 18: 117-123, 1995

P.77 掲載の参考文献

1) Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888-1899, 1999

2) Schoen RT, Vender RJ: Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 86: 449-458, 1989

3) Taha AS, Hudson N, Hawkey CJ et al: Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 334: 1435-1439, 1996

4) Walan A, Bader JP, Classen M et al: Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 320: 69-75, 1989

P.79 掲載の参考文献

1) McCarthy DM: Nonsteroidal antiinflammatory drug-induced ulcers: management by traditional therapies. Gastroenterology 96 (suppl): 662-674, 1989

2) Ekstrom P, Carling L, Wetterhus S et al: Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. Scand J Gastroenterol 31: 753-758, 1996

P.81 掲載の参考文献

1) Giercksky KE, Huseby G, Rugstad HE: Epidemiology of NSAID-related gastrointestinal side effects. Scand J Gastroenterol Suppl 163: 3-8, 1989

2) Walan A, Bader JP, Classen M et al: Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 320: 69-75, 1989

P.83 掲載の参考文献

1) Graham DY, Agrawal NM, Roth SH: Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 2: 1277-1280, 1988

2) Aabakken L, Bjornbeth BA, Weberg R et al: NSAID-associated gastroduodenal damage: does famotidine protection extend into the mid-and distal duodenum? Aliment. Pharmachol Ther 4: 295-303, 1990

3) Simon TJ, Berger ML, Hoover ME et al: A dose-ranging study of famotidine in prevention of gastroduodenal lesions associated with non-steroidal anti-inflammatory drugs (NSAIDs): results of a U. S. multicenter trial. Am J Gastroenterol 89: A 1644 (abstract), 1994

P.85 掲載の参考文献

1) Hawkey CJ, Tulassay Z, Szczepanski L et al: Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 352: 1016-1021, 1998

P.87 掲載の参考文献

1) Hosking SW, Ling TK, Chung SC et al: Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. Lancet 343: 508-510, 1994

P.89 掲載の参考文献

1) Hawkey CJ, Jeffrey AK, Szczepanski L et al: A comparison of omeprazole and misoprostol for treating and preventing ulcers associated with non steroidal anti-inflammatory drugs. N Engl J Med 338: 727-734, 1998

2) Chan FKL, Sung JJY, Chung SCS et al: Randomised eradication of H. pylory before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 350: 975-979, 1997

P.91 掲載の参考文献

1) Fries JF: NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisa1. J Rheumatol Suppl 28: 6-10, 1991

2) Walt RP: Misoprostol for the treatment of peptic ulcer and antiinflammatory-drug-induced gastroduodenal ulceration. N Engl J Med 327: 1575-1580, 1992

3) Hawkey CJ, Karrasch JA, Szczepanski L et al: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338: 727-734, 1998

P.94 掲載の参考文献

1) Bhargava DK, Dasarathy S, Atmakuri SP et al: Comparative efficacy of emergency endoscopic sclerotherapy for active variceal bleeding due to cirrhosis of the liver, non-cirrhotic portal fibrosis and extrahepatic portal venous obstruction. J Gastroenterol Hepatol 5: 432-437, 1990

2) Terblanche J, Northover JM, Bornman P et al: A prospective evaluation of injection sclerotherapy in the treatment of acute bleeding from esophageal varices. Surgery 85: 239-245, 1979

3) Bhargava DK, Singh B, Dogra R et al: Prospective randomized comparison of sodium tetradecyl sulfate and polidocanol as variceal sclerosing agents. Am J Gastroenterol 87: 182-186, 1992

P.98 掲載の参考文献

1) Walan A, Bianchi-Porro G, Hentschel E et al: Maintenance treatment with cimetidine in peptic ulcer disease for up to 4 years. Scand J Gastroenterol 22: 397-405, 1987

2) Jensen DM, Machicado GA, Kovacs TO et al: CURE Hematostasis Research Group. Long-term recurrence rates of peptic ulceration and rebleeding with H2 maintenance, surgery or no maintenance therapy. Gastroentelogy 96 (suppl 1): A239, 1989 (Abstr)

3) Sonnenberg A, Olson CA, Zhang J: The effect of antibiotic therapy on bleeding from duodenal ulcer. Am J Gastroenterol 94: 950-954, 1999

P.101 掲載の参考文献

1) Graham DY, Hepps KS, Ramirez FC et al: Treatment of Helicobacter pylori: : reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 28: 939-942, 1993

2) Santander C, Gravalos RG, Gomez-Cedenilla A et al: Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: Prospective nonrandomized trial on 125 patients. Am J Gastroenterol 91: 1549-1552, 1996

3) Labenz J, B?rsch G: Role of Helicobacter Pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion 55: 19-23, 1994

4) Rokkas T, Karameris A, Mavrogeogis A et al: Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease. Gastrointest Endosc 41: 1-4, 1995

5) Jaspersen D, Koerner T, Schorr W et al: Helicobacter pylori eradication reduces the rate of rebleeding in ulcer haemorrhage. Gastrointest Endosc 41: 5-7, 1995

6) Ponell KU, Bell GD, Bolton GH et al: Helicobacter pylori eradication in patients with peptic ulcer disease: Clinical consequences and financial implications. Quat J Med 87: 283-290, 1994

P.103 掲載の参考文献

1) Walt RP, Cottrell J, Mann SG et al: Continuous intravenous famotidine for haemorrhage from peptic ulcer. Lancet 340: 1058-1062, 1992

2) Collins R, Langman M: Treatment with histamine H2 antagonists in acute upPer gastrointestinal hemorrhage. Implications of randomized trials. N Engl J Med 313: 660-666, 1985

3) Daneshmend TK, Hawkey CJ, Langman MJ et al: Omeprazole versus placedo for acute upper gastrointestinal bleeding: randomised double blind controlled trial. BMJ 304: 143-147, 1992

P.105 掲載の参考文献

1) Chiba N, Rao BV, Rademaker JW et al: Meta- analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 87: 1716-1727, 1992

2) Treiber G: The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. Am J Gastroenterol 91: 246-257, 1996

P.107 掲載の参考文献

1) Rauws EA, Tytgat GN: Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 335: 1233-1235, 1990

2) Graham DY, Lew GM, Klein PD et al: Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann lntern Med 116: 705-708, 1992

3) Rabeneck L, Ransohoff DF: Is Helicobacter pylori a cause of duodenal ulcer？ A methodologic critique of current evidence. Am J Med 91: 566-572, 1991

P.109 掲載の参考文献

1) George LL, Borody TJ, Andrews P et al: Cure of duodenal ulcer after eradication of Helicobacter pylori. Med J Aust 153: 145-149, 1990

2) Graham DY, Lew GM, Malaty HM et al: Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 102: 493-496, 1992

P.111 掲載の参考文献

1) Van der Hulst RW, Tytgat GN: Helicobacter pylori and peptic ulcer disease. Scand J Gastroenterol Supple 220: 10-18, 1996

2) Hopkins RJ, Girardi LS, Turney EA: Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 110: 1244-1252, 1996

P.113 掲載の参考文献

1) Goh KL, Boonyapisit S, Lai KH et al: Prevention of duodenal ulcer relapse with omeprazole 20 mg daily: arandomized double-blind, placebo-controlled study. J Gastroenterol Hepatol 10: 92-97, 1995

2) Santander C, Gravalos RG, Gomez-Cedenilla A et al: Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. Am J Gastroenterol 91: 1549-1552, 1996

P.115 掲載の参考文献

1) Coghlan JG, Gilligan D, Humphries H et al: Campylobacter pylori and recurrence of duodenal ulcers--a 12-month follow-up study. Lancet 2: 1109-1111, 1987

2) Marshall BJ, Goodwin CS, Warren JR et al: Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 2: 1437-1442, 1988

3) Rauws EA, Tytgat GN: Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 335: 1233-1235, 1990

P.117 掲載の参考文献

1) Rauws EA, Langenberg W, Houthoff HJ et al: Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 94: 33-40, 1988

2) Hosking SW, Ling TK, Chung SC et al: Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. Lancet 343: 508-510, 1994

P.119 掲載の参考文献

1) Smyth JF, Coleman RE, Nicolson M et al: Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? BMJ 303: 1423-1426, 1991

2) Pater JL, Lofsters WS, Zee B et al: The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol 8: 181-185, 1997

3) Osoba D, Warr DG, Fitch MI et al: Guidelines for the optimal management of chemotherapy-induced nausea and vomiting a consensus. Can J Oncol 5: 381-400, 1995

P.121 掲載の参考文献

1) Andrews PL, Rapeport WG, Sanger GJ: Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci 9: 334-341, 1988

2) 古江尚: 癌化学療法における悪心・嘔吐対策.癌治療と宿主4: 75-85, 1992

3) 住永雅司, 古江尚, 太田和雄ほか: 抗悪性腫瘍剤による悪心・嘔吐に対するGranisetron経口剤の臨床評価-至適用量の検討-. 癌と化学療法 20: 1203-1210, 1993

P.123 掲載の参考文献

1) Hesketh PJ, Gralla RJ, Webb RT et al: Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11, 974 in the control of cisplatin-induced emesis. J Clin Oncol 17: 338-343, 1999

2) Yamakuni H, Sawai H, Maeda Y et al: Probable involvement of the 5-hydroxytryptamine (4) receptor in methotrexate-induced delayed emesis in dogs. J Pharmacol Exp Ther 292: 1002-1007, 2000

P.125 掲載の参考文献

1) 馬場秀夫, 鴻江俊治, 遠藤和也ほか: 消化器癌治療のState of the Art. 癌と化学療法 27: 1233-1246, 2000

2) 小西敏郎, 出月康夫, 渡辺弘ほか: 胃癌・大腸癌の術後補助療法におけるUFT単独投与とOK-432 併用投与の比較. 癌と化学療法25: 887-900, 2000

P.127 掲載の参考文献

1) Silverstein FE, Graham DY, Senior JR et al: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial Ann lntern Med 123: 241-249, 1995

2) Chan CC, Boyce S, Brideau C et al: Rofecoxib 〔Vioxx, MK-0966, 4- (4'-methylsulfonyl-phenyl) -3-phenyl-2- (5H) -furanone〕: a potent and orally active cyclooxygenase-2 inhibitor. pharmacological and biochemical profiles. J Pharmacol Exp Ther 290: 551-560, 1999

3) Mohammed S, Croom DW 2nd: Gastropathy due to celecoxib, a cyclooxygenase-2 inhibitor. N Engl J Med 340: 2005-2006, 1999

P.128 掲載の参考文献

1) Gisbert JP, Gisbert JL, Marcos S et al: Seven-day ‘rescue': therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs ranitidine bismuth citrate, tetracycline and metronidazole. Aliment pharmacol Ther 13: 1311-1316, 1999

2) Gomollon F, Ducons JA, Ferrero M et al: Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. Helicobacter 4: 222-225, 1999

P.131 掲載の参考文献

1) Borsch G, Wegener M, Mai U et al: Efficiency of oral triple therapy to eradicate Campylobacter pylori. In: Gastroduodenal pathology and Campylobacter pylori. ed by Megraud F, Lamouliatte H Amsterdam, Elsevier 1989, pp 595-598

2) Labenz J, Gyenes E, Ruhl GH et al: Efficiency of oral triple therapy (BSS/metronidazole/tetracycline) to eradicate HP in DU disease. Ir J Med Sci 161: 90, 1992

3) Byerdorffer E, Mannes GA, Sommer A et al: High dose omeprazole treatment combined with amoxicillin eradicates Helicobacter pylori. Eur J Gastroenterol Hepatol 4: 697-702, 1992

P.133 掲載の参考文献

1) Bazzoli F, Zagari RM, Fossi S et al: Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 6: 773-777, 1994

2) Bell GD, Powell KU, Burridge SM et al: Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 9: 41-46, 1995

P.135 掲載の参考文献

1) Laine L, Frantz JE, Baker A et al: A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. Aliment Pharmacol Ther 11 : 913-917, 1997

2) Miyaji H, Azuma T, Ito S et al: Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. Aliment Pharmacol Ther 11 : 1131-1136, 1997

P.137 掲載の参考文献

1) Lind T, Veldhuyzen van Zanten SV, Unge P et al: Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH 1 Study. Helicobacter 1 : 138-144, 1996

2) Hentschel E, Brandstatter G, Dragosics B et al: Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 328: 308-312, 1993

P.138 掲載の参考文献

1) Grigoriev PY, Zoseeva OV, Yokovenko AV et al: Ranitidine antimicrobial therapy vs omeprazole antimicrobial therapy for Helicobacter pylori associated peptic ulcer. Am J Gastroenterol 89: 1392, 1994

2) Catalano F, Privitera U, Branciforte G et al: Omeprazole plus clarithromycin: efficacy of two treatment regimens on Helicobacter pylori positive duodenal ulcer. Ann Exp Clin Med 34: 93-97, 1995

P.141 掲載の参考文献

1) McLaren A, Donnelly C, McDowell S et al: The role of ranitidine bismuth citrate in significantly reducing the emergence of Helicobacter pylori strains resistant to antibiotics. Helicobacter 2: 21- 26, 1997

P.143 掲載の参考文献

1) Furuta T, Ohashi K, Kosuge K et al: CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 65: 552-561, 1999

2) Termanini B, Gibril F, Sutliff VE et al: Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med 104: 422-430, 1998

下部消化管●小腸・大腸疾患

P.147 掲載の参考文献

1) van Hees PA, Bakker JH, van Tongeren JH: Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut 21: 632-635, 1980

2) Schroder H, Campbell DE: Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther 13: 539-551, 1972

3) Schroeder KW, Tremaine WJ, Ilstrup DM: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317: 1625-1629, 1987

P.149 掲載の参考文献

1) Lofberg R, Thomsen O, Langholtz E et al: Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 8: 623-629, 1994

2) Rutgeerts P: Budesonide enemas for topical therapy of ulcerative colitis. Can J Gastroenterol 4: 415-416, 1990

3) Porro GB, Prantera C, Campieri M et al: Comparative trial of methyl prednisolone and budesonide enemas in active distal ulcerative colitis. J Gastroenterol Hepatol 6: 125-130, 1994

4) The Danish Budesonide Study Group: Budesonide enema in distal ulcerative colitis: a randomized dose-response trial with prednisolone enama as positive control. J Gastroenterol 26: 1225-1230, 1991

P.151 掲載の参考文献

1) Kosaka T, Sawada K, Ohnishi K et al: Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn's disease. Internal Medicine 38: 102-111, 1999

2) 下山孝, 澤田康史, 大西国夫ほか: 潰瘍性大腸炎の白血球系細胞吸着・除去療法. 日内会誌88: 724-730, 1999

3) 澤田康史, 大西国夫, 江藤明盛ほか: 潰瘍性大腸炎に対する白血球系細胞除去療法. 日本アフェレシス学会雑誌18: 99-104, 1999

P.153 掲載の参考文献

1) 棟方昭博, 村田有志, 鈴木和夫ほか: 潰瘍性大腸炎での免疫抑制剤投与例の検討. 厚生省特定疾患難治性炎症性腸管障害調査研究班, 平成4年度研究報告書, 1993, pp 94-97

2) Dubinsky MC, Lamothe S, Yang HY et al: Pharmacogenomics and metabolite measurement for 6-Mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118: 705-713, 2000

P.156 掲載の参考文献

1) Lichtiger S, Present DH: Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 336: 16-19, 1990

2) Kozarek R, Bedard C, Patterson D et al (Pacific Northwest Gastroenterology Society): Cyclosporin use in the precolectomy chronic ulcerative colitis patient: A community experience and its relationship to prospective and controlled clinical trials. Am J Gastroenterol 90: 2093-2096, 1995

3) Sandborn WJ: A clinical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1 : 48-63, 1995

4) Sandborn WJ: A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 91: 423-433, 1996

P.159 掲載の参考文献

1) Jick H, Walker AM: Cigarette smoking and ulcerative colitis. N Engl J Med 308: 261-263, 1983

2) Haynes RB: Incorporating allocation concealment and blinding in randomized controlled trials. ACP Journal Club 132: A-13, 2000

P.161 掲載の参考文献

1) Dissanayake AS, Truelove SC: A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). Gut 14: 923-926, 1973

2) Ewe K Herfarth C, Malchow H et al: Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. Digestion 42: 224-232, 1989

3) Messori A, Brignola C, Trallori G et al: Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 89: 692-698, 1994

P.163 掲載の参考文献

1) 樋渡信夫: クローン病治療指針改訂案. 厚生省特定疾患難治性炎症性腸管障害調査研究班平成9年度研究報告書 (班長: 下山孝), 1998, pp 104-107

2) Summers RW, Switz DM, Sessions JT Jr et al: National Cooperative Crohn's disease Study: results of drug treatment. Gastroenterology 77: 847-869, 1979

3) Matsueda K, Shoda R, Takazoe M et al: Therapeutic efficacy of cyclic home elemental enteral alimentation in Crohn's disease: Japanese cooperative Crohn's disease study. J Gastroenterol 30: 91-94, 1995

P.165 掲載の参考文献

1) Femandez-Banares F, Bertran X, Esteve-Comas M et al: Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 91: 2498-2499, 1996

2) Pearson DC, May GR Fick GH et al: Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 123: 132-142, 1995

P.167 掲載の参考文献

1) Jewell D, Lennard-Jones JE: Cyclosporin Study Group of Great Britain and Ireland. Oral cyclosporin for chronic active Crohn's disease: a multicentre controlled trial. Eur J Gastroenterol Hepatol 6: 499-505, 1994

2) Kozarek RA, Patterson DJ, Gelfand MD et al: Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann lntern Med 110: 353-356, 1989

P.169 掲載の参考文献

1) van Dullemen HM, van Deventer SJ, Hommes DW et al: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2) Gastroenterology 109: 129-135, 1995

2) Targan SR, Hanauer SB, van Denventer SJ et al: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 337: 1029-1035, 1997

P.171 掲載の参考文献

1) Shanahan F: Anti-TNF therapy for Crohn's disease: a perspective. Inflammatory Bowel Disease 6: 137-139, 2000

P.173 掲載の参考文献

1) Schreiber S, Heinig T, Thiele HG et al: Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 108: 1434-1444, 1995

2) Smeets TJ, Kraan MC, Versendaal J et al: Analysis of serial synovial biopsies in patients with rheumatoid arthritis: description of a control group without clinical improvement after treatment with interleukin 10 or placebo. J Rheumatol 26: 2089-2093, 1999

3) McHutchison JG, Giannelli G, Nyberg L et al: A pilot study of daily subcutaneous interleukin-10 in patients with chronic hepatitis C infection. J Interferon Cytokine Res 19: 1265-1270, 1999

P.175 掲載の参考文献

1) 里見匡迫, 澤田康史, 福田能啓ほか: 炎症性腸疾患の治療法の変遷. 消化器外科19: 1127-1136, 1996

2) 福田能啓, 平川博之: 炎症性腸疾患に対する新しい栄養療法. 消化器科15: 189-197, 1991

P.178 掲載の参考文献

1) Lorenz-Meyer H, Bauer P, Nicolay C et al: Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Scand J Gastroentrol 31: 778-785, 1996

2) Matsueda K, Shoda R, Takazoe M et al: Therapeutic efficacy of cyclic home elemental enteral alimentation in Crohn's disease: Japanese cooperative Crohn's disease study. J Gastroenterol 30 (suppl VIII): 91-94, 1995

P.181 掲載の参考文献

1) Allison AC, Eugui EM: Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 136: 5-28, 1993

2) European Mycophenolate Mofetil Cooperative Study Group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345: 1321-1325, 1995

3) Hassard PV, Vasiliauskas EA, Kam LY et al: Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. Inflamm Bowel Dis 6: 16-20, 2000

4) Fellermann K, Steffen M, Stein J et al: Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 14: 171-176, 2000

P.183 掲載の参考文献

1) Sandbom WJ: Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol 92: 876-879, 1997

2) Lowry PW, Weaver AL, Tremaine WJ et al: Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment -refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis 5: 239-245. 1999

3) 日比紀文, 船越信介: クローン病の治療. Frontiers in Gastroenterology 5: 22-28, 2000

P.189 掲載の参考文献

1) 五島瑳智子, 徐慶一朗, 河喜多竜祥ほか: 最小発育阻止濃度 (MIC) 測定法再改訂について. 29: 76-79, 1981.

P.191 掲載の参考文献

1) 香坂隆夫, 田河学, 鈴木輝明ほか: EHEC感染症における抗菌剤の使用上の問題点-この古くて新しい問題提起. 日本臨床 55: 706-714, 1997

2) 竹田美文: 一次, 二次医療機関のための腸管出血性大腸菌 (O157等) 感染症治療の手引き改訂版. 日本医師会雑誌 118: 1085-11092, 1997

3) 相楽裕子: O157の感染ルートは解明されたのか. 治療法にconsensusは得られたのか. 内科 82: 541-544, 1998

P.193 掲載の参考文献

1) 竹田多恵, 吉野健一, 松田枝里子ほか: Vero毒素吸着剤の開発研究の動向. 日本臨床 55: 751-757, 1997

2) 香坂隆夫, 田川学, 鈴木輝明ほか: EHEC感染症における抗生剤の使用上の問題. 日本臨床 55: 706-714, 1997

P.195 掲載の参考文献

1) Rao PM, Rhea JT, Novelline RA et al: Helical CT technique for diagnosis of appendicitis: prospective evaluation of a focused appendix CT examination. Radiology 202: 139-144, 1997

2) Rao PM, Rhea JT, Novelline RA et al: Helical CT combined with contrast material administered only through the colon for imaging of suspected appendicitis. AJR 169: 1275-1280, 1997

P.198 掲載の参考文献

1) Anonymous: The advanced colorectal cancer meta-analysis project: modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896-903, 1992

2) Machover D, Goldschmidt E, Chollet P et al: Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 4: 685-696, 1986

3) Scheithauer W, Kornek G, Marczell A et al: Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. J Clin Oncol 15: 908-914, 1997

P.201 掲載の参考文献

1) Miller AB, Hoogstraten B, Staquet M et al: Reponing results of cancer treatment. Cancer 47: 207-214, 1981

2) Mantel H, Haenzel W: Statsitical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer lnst 22: 719-748, 1959

3) Cox DR: The Analysis of Binary Data, Methuen, London, United Kingdom, 1970

4) Peto R, Pike MC, Armitage P et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35: 1-39, 1977

P.203 掲載の参考文献

1) Pazdur R, Douillard J-Y, Skillings JR et al: Multicenter phase III study of 5-fluorouracil or UFT in combination with leucovorin in patients with metastatic colorectal cancer. Proc ASCO 18: 263a, 1999

2) Carmichael J, Popdiela T, Radstone D et al: Randomized comparative study of ORZEL?〔oral uracil/tegafur (UFT)〕plus leucovorin versus parenteral 5-fluorouracil plus leucovorin in patients with metastatic colorectal cancer. Proc ASCO 18: 264a, 1999

P.205 掲載の参考文献

1) Kusunoki M, Yanagi H, Kotera H et al: Effects of pharmacokinetic modulating chemotherapy using oral UFT and continuous venous 5FU infusion on the prognosis of irradiated rectal carcinoma with P53 overexpression. 1nt J Oncol 13: 653-657, 1998

2) Fujii S, Fukushima M, Shimamoto Y et al: Pharmacokinetic modulation of plasma 5-fluorouracil concentration to potentiate the antitumor activity of continuous venous infusion of 5-fluorouracil. Jpn J Cancer Res 80: 509-512, 1989

3) Piedbois P, Buyse M, Rustum Y et al: (Advanced colorectal cancer meta-analysis project) modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J CIin Oncol 10 : 896-903, 1992

P.207 掲載の参考文献

1) Rougier P, Bugat R, Douillard JY et al: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15: 251-260, 1997

2) Cunningham D, Glimelius B: A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Semin Oncol 26 (suppl 5): 6-12, 1999

3) Van Custem E, Bilijham GH: Irinotecan versus infusional 5-fluorouracil: A phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group. Semin Oncol 26 (suppl 5): 12-20, 1999

P.209 掲載の参考文献

1) Wadler S, Lemberskey B, Atkins M et al: Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastren Cooperative Oncology Group study. J CIin Oncol 9: 1806-1810, 1991

2) Makower D, Walder S: Interferons as biomodulators of fluoropyrimidines in the treatment of colorectal cancer. Semin Oncol 26: 663-671, 1999

3) Villar-Grimalt A, Candel MT, Massuti B et al: A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorecta1 cancer. Br J Cancer 80: 786-791, 1999

P.211 掲載の参考文献

1) 宮島伸宜, 山川達郎: 大腸癌に対する minimally invasive surgery の適応と成績. 日消外会誌31: 1038-1042, 1998.

2) 福永正氣, 木所昭夫, 射場敏明ほか: 右側結腸癌に対する腹腔鏡下手術. 消化器外科 22: 175-187, 1999

3) Okuda J, Tanigawa N: Colon carcinomas may be adequetely treated using laparoscopic methods. Semin Colon Rectal Surg 9: 241-245, 1998

P.213 掲載の参考文献

1) Thun MJ, Namboodiri MM, Heath CW Jr et al: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596, 1991

2) Sawaoka H, Kawano S, Tsuji S et al: Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 274: G1061-G1067, 1998

P.215 掲載の参考文献

1) Gann PH, Manson JE, Glynn RJ et al: Low-dose aspirin and incidence of colorectal tumors in a randomized tria1. J Natl Cancer lnst 85: 1220-1224, 1993

2) Peleg II, Maibach HT, Brown SH et al: Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch lntern Med 154: 394-399, 1994

3) Rosenberg L, Palmer JR, Zauber AG et al: A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence Of large-bowel cancer. J Natl Cancer lnst 83: 355-358, 1991

P.217 掲載の参考文献

1) Ahlquist DA, Wieand HS, Moertel CG et al: Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA 269: 1262-1267, 1993

2) Lang CA, Ransohoff DF: Fecal occult blood screening for colorecta1 cancer. ls mortality reduced by chance selection for screening colonoscopy？ JAMA 271: 1011-1013, 1994

3) Selby JV, Friedman GD, Quesenberry CP Jr et al: A case-control study of screening sigmoidoscopy and mortality from colorecta1 cancer. N Engl J Med 326: 653-657, 1992

P.219 掲載の参考文献

1) Mandel JS, Bond JH, Bradley M et al: Sensitivity, specificity, and positive predictivity of the Hemoccult test in screening for colorectal cancers. The University of Minnesota's Colon Cancer Control Study. Gastroenterology 97: 597-600, 1989

2) Ahlquist DA, Wieand HS, Moertel CG et al: Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA 269: 1262-1267, 1993

3) Lang CA, Ransohoff DF: Fecal occult blood screening for colorecta1 cancer. ls mortality reduced by chance selection for screening colonoscopy？ JAMA 271: 1011-1013, 1994

P.221 掲載の参考文献

1) Mandel JS, Bond JH, Church TR et al: Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328: 1365-1371, 1993

2) Kronborg O, Fenger C, Olsen J et al: Randomised study of screening for colorectal cancer with faecal -occult-blood test. Lancet 348: 1467-1471, 1996

3) Hardcastle JD, Chamberlain JO, Robinson MH et al: Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348: 1472-1477, 1996

P.223 掲載の参考文献

1) Waddell WR, Loughry RW: Sulindac for polyposis of the colon. J Surg Oncol 24: 83-87, 1983

2) Giardiello FM, Hamilton SR, Krush AJ et al: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313-1316, 1993

3) Rao CV, Rivenson A, Simi B et al: Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal antiinflammatory agent. Cancer Res 55: 1464-1472, 1995

P.225 掲載の参考文献

1) Read TE, Read JD, Butterly LF: Importance of adenomas 5 mm or less in diameter that are detected by sigmoidoscopy. N Engl JMed 336: 8-12, 1997

2) Winawer SJ, Zauber AG, 0'Brien MJ et al: Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl JMed 328: 901-906, 1993

P.227 掲載の参考文献

1) Klein KB: Controlled treatment trials in the irritable bowel syndrome: acritique. Gastroenterology 95: 232-241, 1988

P.229 掲載の参考文献

1) Tasman-Jones C: Mebeverine in patients with the irritable colon syndrome: double blind study. N Z Med J 77: 232-235, 1973

2) Inauen W, Halter F: Clinical efficacy, safety and tolerance of mebeverine slow release (200mg) versus mebeverine tablets in patients with irritable bowel syndrome. Drug lnvest 8: 234-240, 1994

3) Kruis W, Thieme C, Weinzierl M et al: A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 87: 1-7, 1984

P.231 掲載の参考文献

1) Maggi CA, Manzini S, Meli A: Octylonium bromide: a smooth muscle relaxant which interferes with calcium ions mobilization. Arch lnt Pharmacodyn 264: 305-323, 1983

2) Drossman DA, Thompson WG, Talley NJ et al: Identification of sub-groups of functional gastrointestinal disorders. Gastroenterol lntl 3: 159-172, 1990

3) Klein KB: Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 95: 232-241, 1988

P.233 掲載の参考文献

1) Young SJ, Alpers D H, Norland CC et al: Psychiatric illness and the irritable bowel syndrome. ；Practical implications for the primary physician. Gastroenterology 70: 162-166, 1976

2) Manning AP, Thompson WG, Heaton KW et al: Towards positive diagnosis of the irritable bowel. Br Med J 2 : 653-654, 1978

3) Mayer EA, Raybould HE: Role of visceral afferent mechanisms in functional bowel disorders. Gastroenterology 99: 1688-1704, 1990

P.235 掲載の参考文献

1) Magni G: The use of antidepressants in the treatment of chronic pain. A review of the current article. Drugs 42: 730-748, 1991

2) Loldrup D, Langemark M, Hansen HJ et al: Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study. Psychopharmacology 99: 1-7, 1989

P.237 掲載の参考文献

1) 正宗研, 福富久之, 松尾裕ほか: 過敏性腸症候群に対するポリカルボフィルカルシウム錠 (HSR-237) の後期第II相試験; 二重盲検法による用量検討試験. 薬理と治療 26(suppl 5): S945-S965, 1988

2) Saito T, Mizutani F, Iwanaga Y et al: Anti-diarrheal and anti-constipative effects of HSR-237, an agent for treating irritable bowel syndrome, in rats and mice. JJ Pharmacot 67(suppl 1): 203, 1995

3) 佐々木大輔, 吉田豊, 棟方昭博ほか: 過敏性腸症候群に対するポリカルボフィルムカルシウム錠 (HSR-237) の臨床評価. 薬理と治療 26(suppl 5): S1045-S1059, 1998

P.239 掲載の参考文献

1) Takenaga H, Magaribuchi T, Tamaki H: Effects of trimebutine maleate (TM-906) on the spontaneous contraction of isolated guinea pig colon. JJ Pharmacol 34: 177-181, 1984

2) 長瀬清, 斉藤雅雄, 高橋建二ほか: Trimebutine の消化器不定愁訴に対する臨床試験. 診療と新薬 19: 347-355, 1982

3) 佐々木大輔: 大腸運動に対する Trimebutine maleate (Cerekinon) の作用についての検討 Therapeutic Research 3: 788-796, 1985

P.241 掲載の参考文献

1) Kilpatrick GJ, Bunce KT, Tyers MB: 5-HT? receptors. Med Res Rev 10: 441-475, 1990

2) Costall B, Naylor RJ: 5-Hydroxytryptamine: new receptors and novel drugs for gastrointestinal motor disorders. Scand J Gastroenterol 8: 769-787, 1990

3) Maxton DG, Morris J, Whorwell PJ et al: Improving clinical trials in irritable bowel syndrome: some practical aspects. Eur J Gastroenterol Hepatol 4: 337-441, 199d2

P.243 掲載の参考文献

1) Klein KB: Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 95: 232-241, 1988

2) Van Outryve M, Milo R, Toussaint J et al: “Prokinetic”treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J Clin Gastroenterol 13: 49-57, 1991

P.245 掲載の参考文献

1) 板橋道朗: 大腸癌術後イレウスに対する大建中湯の有用性. 腸管機能研究会記録集-漢方と腸管機能, 日本医学館, 東京, 1997 pp9-16

2) 堀尾静, 須田賢, 村瀬正治ほか: 癒着性イレウス-特に再発性イレウスに対する漢方治療の効果-. Prog Med 12: 1663-1667, 1992

3) 大藪久則, 松田昌三, 栗栖茂ほか: 癒着性イレウスに対するrandomized trialによる大建中湯の評価. Prog Med 15: 1954-1958, 1995

書評

書評を投稿する

最近チェックした商品履歴

Loading...